Compare XNET & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XNET | LXEO |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.4M | 396.5M |
| IPO Year | 2011 | 2023 |
| Metric | XNET | LXEO |
|---|---|---|
| Price | $4.93 | $4.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 219.1K | ★ 910.0K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.52 | $3.99 |
| 52 Week High | $11.03 | $10.99 |
| Indicator | XNET | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 47.67 |
| Support Level | $4.78 | $4.39 |
| Resistance Level | $6.09 | $5.38 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 35.71 | 15.29 |
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.